Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era-Reference-Cited by-同舟云学术

Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era

Published:2022-08 Issue:8 Volume:22 Page:e716-e729
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Rybinski Brad,Rapoport Aaron P,Badros Ashraf Z.,Hardy Nancy,Kocoglu Mehmet

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference39 articles.

1. Cancer statistics, 2018;Siegel;CA Cancer J Clin,2018

2. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management;Rajkumar;Am J Hematol,2020

3. Up-front carfilzomib, lenalidomide, and dexamethasone with transplant for patients with multiple myeloma: the IFM KRd final results;Roussel;Blood,2021

4. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial;Voorhees;Blood,2020

5. Autologous transplantation and maintenance therapy in multiple myeloma;Palumbo;N Engl J Med,2014

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single‐center experience;Cancer Medicine;2024-06

2. Сравнительный анализ эффективности режимов мобилизации аутологичных гемопоэтических стволовых клеток у больных множественной миеломой;Clinical Oncohematology;2024-02-20

3. Overcoming Barriers to Autologous Stem Cell Transplantation in Multiple Myeloma: Recommendations from a Multidisciplinary Roundtable Discussion;Transplantation and Cellular Therapy;2023-11